Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia

Respiratory Medicine

Volumn 101, Issue 10, 2007, Pages 2224-2226

  El Abiad, Nisreen M ^a   Clifton, Shelley ^b   Nasr, Samya Z ^c  

^a Cairo University   (Egypt)

^b Department of Pediatrics   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Primary ciliary dyskinesia; Pulmonary function testing; rhDNase (dornase alfa)

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; DIURETIC AGENT; DORNASE ALFA;

ADOLESCENT; ARTICLE; BACTERIUM CULTURE; BREATHING EXERCISE; CASE REPORT; CILIARY DYSKINESIA; CLINICAL FEATURE; DISEASE EXACERBATION; EAR INFECTION; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEART DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARTAGENER SYNDROME; LONG TERM CARE; MALE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RETREATMENT; SIBLING;

ADOLESCENT; DEOXYRIBONUCLEASE I; FORCED EXPIRATORY VOLUME; HUMANS; KARTAGENER SYNDROME; LONG-TERM CARE; MALE; NEBULIZERS AND VAPORIZERS; TREATMENT OUTCOME;

EID: 34548282573     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.05.014     Document Type: Article

References (18)

1. Meeks M., and Bush A. Primary ciliary dyskinesia (PCD). Pediatr Pulmonol 29 (2000) 307-316
2. Bush A., Cole P., Hariri M., et al. Primary ciliary dyskinesia: diagnosis and standards of care. Eur Respir J 12 (1998) 982-988
3. Zihlif N., Paraskakis E., Lex C., et al. Correlation between cough frequency and airway inflammation in children with primary ciliary dyskinesia. Pediatr Pulmonol 39 (2005) 551-557
4. Ratjen F. Dornase in non-CF. Pediatr Pulmonol 26 (2004) 154-155
5. Bush A., Payne D., Pike S., et al. Mucus properties in children with primary ciliary dyskinesia. Comparison with cystic fibrosis. Chest 129 (2006) 118-123
6. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 331 (1994) 637-642
7. Hodson M.E., and Shah P.L. RhDNase trials in cystic fibrosis. Eur Respir J 8 (1995) 1786-1791
8. Ellerman A., and Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. Eur Respir J 10 (1997) 2376-2379
9. Corkey C.W.B., Levison H., and Turner J.A.P. The immotile cilia syndrome. Am Rev Respir Dis 124 (1981) 544-589
10. Desai M., Weller P.H., and Spencer D.A. Clinical benefit from nebulized human recombinant DNase in Kartagener's syndrome. Pediatr Pulmonol 20 5 (1995) 307-308
11. Wills P.J., Wodehouse T., Corkery K., et al. Short-term recombinant human DNase in bronchiectasis; effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 154 (1996) 413-417
12. Puchelle E., Zahm J.M., de Bentzmann S., et al. Effect of rhDNase on purulent airway secretions in chronic bronchitis. Eur Respir J 9 (1996) 765-769
13. Nasr S.Z., Strouce P.J., Soskolne E., et al. Efficacy of recombinant human deoxyribonuclease 1 in the hospital management of respiratory syncytial virus bronchiolitis. Chest 120 (2001) 203-208
14. Tomkeiwicz RP, Kishioka C, Freeman J, et al. DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum G, editor. Cilia, mucus, and mucociliary interactions. New York: Marcel Dekker; 1998. p. 333-41.
15. ten Berge M., Brinkhorst G., Kroon A.A., et al. DNase treatment in primary ciliary dyskinesia-assessment by nocturnal pulse oximetry. Pediatr Pulmonol 27 (1999) 59-61
16. Quan J.M., Tiddens H.A.W.M., Sy J.P., et al. Pulmozyme early intervention trial study group. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 139 6 (2001) 813-820
17. Hodson M.E., McKenzie S., Harms H.K., et al. On behalf of the Investigators of the epidemiologic registry of cystic fibrosis. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol 36 (2003) 427-432
18. Eisenberg J.D., Aitken M.L., Dorkin H.L., et al. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr 131 1 (1997) 118-124